ATLANTA — Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival in a mouse model of Lynch syndrome, suggesting that it may be possible to develop a cancer preventive vaccine for patients with Lynch syndrome, according to data presented at the AACR Annual Meeting 2019, March 29-April 3.
“Lynch syndrome is an inherited condition that affects about one in every 280 individuals in the United States,” said Steven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine in New York; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center. “People with Lynch syndrome have a 70 to 80 percent lifetime risk of colorectal cancer, as well as an increased risk for other types of cancer, including small intestine, stomach, endometrial, bladder, and ovarian cancers.
“Currently, frequent screening to detect precancers and early-stage cancer is the main approach used to prevent cancer in people with Lynch syndrome, although some people have risk-reducing surgeries and some take aspirin for colorectal cancer prevention,” continued Lipkin, who is also a member of the Sandra and Edward Meyer Cancer Center and the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine. “We are extremely encouraged by our preclinical data, which suggest that rationally designed cancer vaccines may prevent some cancers associated with Lynch syndrome. We are in the process of designing a clinical trial to test this hypothesis.”
The genetic mutations that cause Lynch syndrome prevent the proper repair of damaged DNA, leading to the accumulation of mutations in certain parts of the genome called coding microsatellites, explained Lipkin. The coding microsatellite mutations generate novel or modified proteins called neoantigens, which can be recognized by the patient’s immune system but usually do not yield a sufficiently robust immune response to prevent cancers from developing, he added.
In this study, Lipkin and colleagues investigated whether vaccinating mice with Lynch syndrome-associated neoantigens could stimulate a robust immune response that would have antitumor activity.
One of the first steps the researchers took was to analyze intestinal tumors from Lynch syndrome mice for mutations in the coding microsatellites. They identified 13 coding microsatellites that had at least one mutation that occurred in 15 percent or more of the tumors.
Further analysis was conducted to determine which mutations might generate neoantigens and what the peptide sequences of these neoantigens were. The team then tested how effective the 10 most promising neoantigens were at inducing an immune response in mice. They found four of the neoantigens generated from coding microsatellite mutations induced robust neoantigen-specific immune responses.
Vaccination of Lynch syndrome mice with the four neoantigens induced robust neoantigen-specific immune responses. It also significantly reduced intestinal tumor burden and improved survival compared with nonvaccinated Lynch syndrome mice. In nonvaccinated Lynch syndrome mice, the median intestinal tumor burden was 61 mg and overall survival was 241 days, compared with 31 mg and 380 days, respectively, in vaccinated Lynch syndrome mice.
Combining vaccination and administration of the nonsteroidal anti-inflammatory drug naproxen significantly improved overall survival for the Lynch syndrome mice compared with vaccination alone; in mice receiving the combination treatment, overall survival was 541 days versus 380 days in mice receiving only the vaccine.
“Our preclinical data are very exciting because they provide strong support for continuing the investigation and development of immunoprevention strategies for patients with Lynch syndrome,” said Lipkin.
According to Lipkin, the main limitation of the study is that it is a preclinical study, which means that there is still a lot of work to be done before we can know if this strategy will prevent cancer in patients with Lynch syndrome.
This study was funded by the National Cancer Institute (NCI). Lipkin declares no personal conflicts of interest. Two co-investigators on his NCI grant are employees of the immunotherapy company Nouscom.